Back
Emergent BioSolutions 10K Form
Sell
44
EBS
Emergent BioSolutions
Last Price:
9.48
Seasonality Move:
13.84%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-02 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-12-11 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-08-09 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-05-10 | 10Q | EBS/Emergent BioSolutions Quarterly |
2022-11-09 | 10Q | EBS/Emergent BioSolutions Quarterly |
2022-08-02 | 10Q | EBS/Emergent BioSolutions Quarterly |
Receive EBS News And Ratings
See the #1 stock for the next 7 days that we like better than EBS
EBS Financial Statistics
Sales & Book Value
Annual Sales: | $1.02B |
---|---|
Cash Flow: | $147.9M |
Price / Cash Flow: | 3.62 |
Annual Sales: | $9.40 |
Price / Book: | 1 |
Profitability
EPS (TTM): | -4.10000 |
---|---|
Net Income (TTM): | $-208.8M |
Gross Margin: | $317.6M |
Return on Equity: | -35.94% |
Return on Assets: | -12.27% |
Emergent BioSolutions Earnings Forecast
Key Emergent BioSolutions Financial Ratios
- The Gross Profit Margin over the past 22 years for EBS is 31.05%.
- The Selling, General & Administrative Expenses for EBS have been equal to 36.01% of Gross Profit Margin.
- The Research & Development expenses have been 10.89% of Revenue.
- The Interest Expense is -11.56% of Operating Income.
- The Net Earning history of EBS is -74.34% of Total Revenues.
- Per Share Earnings over the last 23 years have been positive in 12 years.
Emergent BioSolutions Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | EBS |
CUSIP: | 29089Q |
Website: | emergentbiosolutions.com |
Debt
Debt-to-Equity Ratio: | 1.3 |
---|---|
Current Ratio: | 2.88 |
Quick Ratio: | 1.18 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 3.14 |
EBS Technical Analysis vs Fundamental Analysis
Sell
44
Emergent BioSolutions (EBS)
is a Sell
Is Emergent BioSolutions a Buy or a Sell?
-
Emergent BioSolutions stock is rated a Sell
The current Emergent BioSolutions [EBS] share price is $9.40. The Score for EBS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.